# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expa...
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 ...
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appe...
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.